Vical and AEterna Zentaris -- Shining Stars in a Booming Sector
June 09 2011 - 8:16AM
Marketwired
Shares of companies focused on cancer treatment have been volatile
this month following the much-anticipated annual meeting of the
American Society for Clinical Oncology, also known as ASCO. While
positive data initially drove shares of several biotech firms
higher, a barrage of profit taking followed. The Bedford Report
examines the outlook for companies in the Healthcare Sector and
provides stock analysis on Vical, Inc. (NASDAQ: VICL) and AEterna
Zentaris Inc. (NASDAQ: AEZS). Access to the full company reports
can be found at:
www.bedfordreport.com/VICL
www.bedfordreport.com/AEZS
Cancer, projected to become the leading cause of death worldwide
this year by the World Health Organisation, has emerged as the
costliest disease, costing the global economy nearly a trillion
dollars a year. With cancer drugs alone costing the United States
more than $30 million a year, it is clearly a lucrative sector for
investors.
It is also an inherently risky sector. Earlier this year Reuters
published research from BioMed Tracker and BIO, which claims that
the cancer drug success rate is a mere 4.7 percent. Upon revealing
the study, the agency's Oncologic Drugs Advisory Committee endorsed
several FDA proposals for tightening the accelerated approval
standards, recommending that sponsors generally be required to
conduct randomized trials rather than single-arm studies, and that
there be more extensive postmarketing studies to confirm clinical
benefit.
The Bedford Report releases investment research on the
Healthcare Sector so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.bedfordreport.com and get
exclusive access to our numerous analyst reports and industry
newsletters.
AEterna Zentaris Inc. is a late-stage oncology drug development
company currently investigating potential treatments for various
cancers including colorectal, multiple myeloma, endometrial,
ovarian, prostate and bladder cancer. During the most recent
quarter, the company reached an agreement with Yakult Honsha Co.
Ltd. for the development, manufacture and commercialization of
AEterna Zentaris' lead anticancer compound, perifosine, in
Japan.
The Bedford Report provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above-mentioned publicly traded companies. The Bedford Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.bedfordreport.com/disclaimer.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024